erad
smallpox
diseas
caus
death
hundr
million
peopl
mani
centuri
accomplish
primarili
use
replicationcompet
vaccinia
viru
strain
vaccin
tradit
firstgener
smallpox
vaccin
well
recent
develop
cell
culturederiv
secondgener
smallpox
vaccin
current
licens
smallpox
vaccin
unit
state
inocul
vaccin
recipi
scarif
skin
surfac
also
known
percutan
skin
cutan
vaccin
rare
sever
advers
reaction
caus
vaccin
includ
gener
vaccinia
eczema
vaccinatum
recent
recogn
case
myopericard
limit
use
vaccin
routin
prevent
vaccin
gener
populac
absenc
immedi
risk
exposur
variola
viru
etiolog
agent
smallpox
pathogen
orthopoxvirus
monkeypox
viru
thu
earli
effort
made
develop
safer
smallpox
vaccin
attenu
exist
strain
vaccinia
viru
part
effort
modifi
vaccinia
viru
ankara
mva
develop
earli
mva
deriv
chorioallantoi
vaccinia
viru
ankara
cva
strain
vaccinia
viru
passag
chick
embryo
fibroblast
cef
cell
cours
passag
cva
cef
cell
sever
gene
mainli
hostrang
immunomodulatori
gene
lost
result
sever
attenu
mva
viral
genom
lost
passag
cef
cell
mva
replic
product
mammalian
cell
mva
extens
evalu
differ
anim
model
clinic
trial
found
less
reactogen
compar
replicationcompet
first
second
gener
smallpox
vaccin
mva
licens
smallpox
vaccin
europ
canada
current
undergo
clinic
develop
unit
state
sever
attenu
mva
consequ
loss
capac
replic
effici
mammalian
cell
evid
inabl
produc
vaccin
take
pustular
lesion
develop
inocul
site
vaccinia
viru
inocul
skin
surfac
apart
potenti
use
smallpox
vaccin
immunocompromis
individu
mva
capac
accommod
heterolog
dna
express
encod
protein
thu
serv
use
viral
vector
vaccin
develop
differ
type
pathogen
sever
recombin
mva
vector
express
heterolog
protein
differ
human
pathogen
variou
phase
clinic
develop
mvavector
vaccin
clinic
trial
includ
express
human
immunodefici
viru
antigen
mycobacterium
tuberculosi
antigen
malaria
antigen
human
papilloma
viru
antigen
hepat
c
antigen
respiratori
syncyti
viru
antigen
influenza
viru
antigen
epsteinbarr
viru
antigen
recent
ebola
viru
antigen
sever
mvavector
vaccin
also
evalu
preclin
studi
preclin
clinic
studi
mva
recombin
mva
vector
unlik
replicationcompet
vaccinia
viru
strain
inocul
subject
via
intramuscular
intraderm
subcutan
rout
although
mva
demonstr
better
safeti
profil
replicationcompet
vaccinia
viru
rel
larg
inoculum
volum
mva
recombin
mva
typic
use
small
anim
model
nonhuman
primateshuman
respect
often
result
local
reaction
site
inocul
includ
muscl
ach
pain
tender
addit
inocul
prophylact
therapeut
regimen
needl
syring
problemat
peopl
global
problem
commonli
call
needl
phobia
fear
needl
common
phraseolog
although
use
needlefre
inject
devic
jet
injector
becom
increasingli
popular
hypoderm
syring
needl
remain
wide
use
deliveri
prophylact
therapeut
remedi
previous
describ
recombin
vaccinia
viru
sever
attenu
plaqu
format
permiss
cell
line
due
delet
gene
encod
protein
respect
extracellular
virion
form
vaccinia
viru
sever
attenu
growth
characterist
viru
reminisc
properti
mva
elicit
vacciniaspecif
igg
neutral
antibodi
balbc
mice
inocul
scarif
base
tail
intranas
challeng
model
use
western
reserv
strain
vaccinia
viru
viru
confer
compar
level
protect
mice
vaccin
clonal
isol
dryvax
cours
work
antibodi
robust
cellmedi
immun
respons
inocul
recombin
mva
vector
skin
also
report
suggest
percutan
inocul
mva
may
elicit
equival
higher
immun
respons
subcutan
inject
work
describ
demonstr
mous
model
percutan
inocul
mva
elicit
protect
immun
respons
lethal
intranas
challeng
western
reserv
wr
strain
vaccinia
viru
low
dose
mva
lower
morbid
record
mice
vaccin
via
percutan
rout
immun
via
intramuscular
subcutan
rout
addit
show
two
model
percutan
inocul
recombin
mva
express
heterolog
antigen
elicit
specif
immun
respons
includ
neutral
antibodi
level
compar
subcutan
inocul
recombin
mva
express
herp
simplex
viru
glycoprotein
elicit
igg
neutral
antibodi
recombin
mva
express
hemagglutinin
influenza
elicit
protect
immun
respons
inocul
percutan
rout
data
suggest
vaccin
via
percutan
rout
effici
stimul
protect
immun
respons
may
find
clinic
relev
immun
mva
mvavector
vaccin
modifi
vaccinia
viru
ankara
mva
atcc
provid
dr
linda
wyatt
bernard
moss
niaidnih
vaccinia
viru
strain
western
reserv
vvwr
atcc
provid
dr
bernard
moss
previous
describ
construct
recombin
mva
express
herp
simplex
viru
type
glycoprotein
gene
strain
ms
insert
delet
ii
region
mva
homolog
recombin
express
glycoprotein
driven
synthet
vaccinia
earlyl
promot
recombin
mva
express
hemagglutinin
influenza
viru
rgaviet
mvaha
construct
homolog
recombin
gene
delet
iii
region
mva
express
influenza
driven
vaccinia
promot
mva
recombin
mva
vector
prepar
primari
chick
embryo
fibroblast
cell
cef
cell
atcc
infect
appropri
viru
previous
describ
partial
purifi
virus
obtain
pass
infect
cell
lysat
sucros
cushion
mva
mva
recombin
titer
cell
monolay
vvwr
prepar
infect
cell
atcc
also
partial
purifi
sucros
cushion
titer
cell
monolay
atcc
attenu
influenza
viru
rgaviet
grown
allanto
caviti
embryon
egg
titrat
mdck
cell
cell
cultiv
regularli
maintain
dmem
contain
fetal
bovin
serum
mdck
cell
gentamicin
balbc
mice
week
old
obtain
jackson
laboratori
bar
harbor
main
mice
receiv
feed
water
freeli
anim
studi
protocol
work
describ
manuscript
approv
institut
anim
care
use
committe
iacuc
center
biolog
evalu
research
usfda
cberfda
intramuscular
inocul
muscl
hind
leg
subcutan
inocul
base
tail
use
tuberculin
syring
affix
needl
perform
previous
describ
tail
scarif
anesthet
anim
also
perform
previous
describ
briefli
inoculum
dilut
steril
endotoxinfre
phosphatebuff
salin
pb
desir
unit
dose
contain
per
mice
anesthet
intraperiton
inject
avertin
tribromoethanol
tertamyl
alcohol
sigmaaldrich
st
loui
missouri
dilut
pb
per
gram
bodi
weight
use
needl
needl
scratchespunctur
made
base
tail
inoculum
appli
scarifi
surfac
vaccinia
viru
strain
wr
attenu
influenza
viru
rgaviet
reassort
vaccin
strain
base
influenza
apuerto
use
challeng
experi
intranas
mous
challeng
dose
ten
lethal
dose
equival
x
pfu
vvwr
use
challeng
rgaviet
dose
pfu
use
previous
determin
dose
lethal
influenza
viru
challeng
model
mice
anesthet
intraperiton
inject
avertin
per
gram
bodi
weight
follow
inocul
challeng
viru
total
suspens
nare
per
nari
previous
describ
mice
monitor
weigh
daili
two
week
post
challeng
mice
lost
initi
bodi
weight
consid
reach
studi
endpoint
human
euthan
per
iacucapprov
anim
studi
protocol
test
antisera
antigenspecif
antibodi
igg
perform
standard
enzymelink
immunosorb
assay
elisa
elisa
vacciniaspecif
antibodi
perform
use
psoralenuvinactiv
vaccinia
viru
dryvax
antigen
previous
describ
gdspecif
igg
elisa
use
partiallypurifi
glycoprotein
ngwell
antigen
neutral
assay
perform
immulon
plate
fisher
scientif
tissu
cultur
plate
corn
respect
previous
describ
influenza
viru
igg
quantifi
use
sanofi
pasteur
inactiv
rgaviet
vaccin
cber
refer
antigen
coat
antigen
immulon
plate
coat
cber
refer
antigen
plate
store
overnight
plate
wash
phosphatebuff
salin
contain
pbst
block
pbst
contain
fetal
bovin
serum
hour
subsequ
incub
antigen
test
serum
sampl
complet
assay
follow
standard
elisa
protocol
previous
describ
test
antisera
neutral
influenza
viru
rgaviet
attenu
vaccin
strain
gener
revers
genet
perform
use
microneutr
assay
previous
describ
presenc
viru
detect
use
biotinconjug
antibodi
influenza
np
clone
milipor
billerica
usa
follow
hrplabel
streptavidin
kpl
gaithersburg
md
usa
mice
vaccin
pfu
via
subcutan
percutan
rout
control
group
vaccin
pfu
mva
seven
day
vaccin
mice
euthan
spleen
collect
dissect
mice
lymphocyt
isol
spleen
homogen
previous
describ
spleen
cell
cultur
tissu
cultur
plate
restimul
live
strain
ms
multipl
infect
cultur
supernat
harvest
hour
clarifi
cell
centrifug
test
captur
elisa
describ
reagent
obtain
bd
pharmingen
unpair
twotail
student
ttest
statist
comparison
antibodi
titer
perform
use
graphpad
prism
softwar
graphpad
softwar
inc
kaplanmei
surviv
logrank
test
perform
use
sigmaplot
softwar
systat
softwar
inc
use
compar
differ
number
surviv
anim
variou
treatment
group
viru
challeng
case
p
valu
indic
statist
signific
differ
treatment
group
preliminari
experi
investig
util
percutan
rout
deliveri
mva
observ
mva
deliv
tail
scarif
statist
insignific
p
elicit
higher
vacciniaspecif
igg
respons
protect
mice
dose
pfu
deliv
intramuscular
rout
fig
experi
use
pfu
mva
allow
us
observ
differ
antibodi
respons
diseas
progress
protect
two
immun
rout
thu
subsequ
experi
lower
dose
mva
evalu
group
mice
vaccin
pfu
mva
via
intramuscular
subcutan
percutan
rout
comparison
set
three
group
mice
similarli
vaccin
pfu
licens
smallpox
vaccin
via
three
rout
untreat
group
includ
control
three
week
vaccin
serum
sampl
obtain
mice
test
vacciniaspecif
antibodi
elisa
use
inactiv
dryvax
antigen
among
mice
mva
treatment
cohort
igg
respons
detect
mice
subcutan
group
percutan
group
untreat
mice
mice
mva
intramuscular
group
detect
igg
time
point
contrast
three
mice
intramuscular
subcutan
group
respect
cohort
detect
level
igg
fig
week
postimmun
mice
challeng
intranas
lethal
dose
vvwr
mice
untreat
group
show
sever
symptom
infect
reach
studi
endpoint
weight
loss
day
postchalleng
euthan
fig
except
mous
mvaintramuscular
group
mice
vaccin
mva
surviv
among
mva
vaccin
anim
mice
intramuscular
group
lost
weight
fig
mean
peak
loss
day
postchalleng
weight
loss
among
mva
subcutan
percutan
group
similar
peak
loss
day
day
respect
howev
mice
mva
percutan
group
recov
quickli
origin
mean
bodi
weight
day
subcutan
group
mean
weight
among
treatment
group
fig
averag
peak
weight
loss
intramuscular
subcutan
percutan
group
respect
anoth
experi
mice
group
five
vaccin
pfu
pfu
mva
scarif
two
group
similarli
vaccin
pfu
pfu
control
group
scarifi
pb
antisera
collect
three
week
mice
challeng
vvwr
none
mice
pb
group
detect
igg
succumb
vvwr
infect
tabl
mice
pfu
mva
group
detect
igg
mva
group
detect
igg
howev
mice
surviv
pfu
pfu
mva
respect
cohort
mice
pfu
pfu
group
respect
seroposit
three
five
mice
cohort
surviv
vvwr
challeng
tabl
set
data
suggest
mous
model
mva
inocul
percutan
rout
elicit
equival
greater
protect
immun
respons
inocul
via
intramuscular
subcutan
rout
mva
attract
vector
use
express
transgen
use
express
antigen
varieti
pathogen
similar
studi
investig
mva
smallpox
vaccin
preclin
clinic
evalu
mvavector
vaccin
develop
reli
predominantli
use
intramuscular
intraderm
subcutan
rout
mva
deliveri
order
determin
whether
percutan
rout
use
evalu
mvavector
recombin
vaccin
recombin
mva
express
glycoprotein
herp
simplex
viru
strain
ms
evalu
immunogen
balbc
mous
model
recombin
mva
gene
encod
glycoprotein
insert
delet
ii
site
mva
homolog
recombin
group
mice
vaccin
three
dose
level
pfu
pfu
pfu
dose
level
administ
subcutan
percutan
control
group
receiv
pfu
mva
subcutan
treatment
group
vaccin
use
primeboost
immun
strategi
previous
describ
antisera
collect
week
prime
vaccin
well
week
boost
test
igg
time
point
use
partiallypurifi
glycoprotein
antigen
fig
antisera
collect
time
point
also
test
neutral
antibodi
fig
antisera
obtain
mice
vaccin
mva
vector
detect
specif
antibodi
time
point
specif
antibodi
detect
antisera
obtain
mice
vaccin
time
point
fig
mean
igg
titer
prime
vaccin
standard
deviat
sd
sd
sd
pfu
pfu
pfu
respect
subcutan
cohort
three
dosag
group
vaccin
via
percutan
rout
mean
igg
titer
sd
sd
sd
obtain
respect
two
five
mice
mous
pfu
pfu
subcutan
group
respect
well
mous
pfu
percutan
group
seroconvert
three
week
prime
vaccin
higher
antibodi
titer
obtain
across
board
group
follow
booster
vaccin
thu
time
point
ie
week
booster
vaccin
mean
igg
titer
sd
sd
sd
record
pfu
pfu
pfu
respect
subcutan
cohort
two
five
mice
pfu
subcutan
group
still
fail
seroconvert
booster
vaccin
mice
percutan
vaccin
group
seroconvert
time
point
time
point
mean
igg
titer
three
percutan
group
pfu
pfu
pfu
sd
sd
sd
respect
serum
sampl
obtain
time
point
test
abil
neutral
infect
vero
cell
similar
igg
elisa
result
antisera
mva
control
group
neutral
mean
serum
neutral
sn
titer
level
quantit
low
modest
neutral
antibodi
titer
detect
vaccin
mice
tabl
subcutan
vaccin
subgroup
mean
sn
titer
obtain
pfu
pfu
pfu
group
respect
sn
titer
three
dosag
percutan
group
respect
anoth
experi
cellular
immun
respons
evalu
mice
vaccin
pfu
mva
subcutan
pfu
either
subcutan
percutan
spleen
cell
harvest
mice
day
vaccin
test
cytokin
secret
previous
describ
meseda
et
al
spleen
cell
restimul
vitro
live
infect
strain
ms
multipl
infect
supernat
collect
cultur
spleen
cell
test
level
wherea
level
supernat
spleen
mvainfect
mice
detect
mice
group
detect
level
tabl
mean
level
pgml
pgml
obtain
subcutan
percutan
group
respect
similarli
level
pgml
pgml
subcutan
percutan
group
respect
taken
togeth
set
data
suggest
inocul
recombin
scarif
capabl
elicit
antigenspecif
immun
respons
compar
higher
deliveri
subcutan
inocul
mva
use
vector
express
heterolog
antigen
delet
site
mva
includ
delet
ii
delet
iii
site
commonli
use
insert
transgen
order
broaden
understand
util
percutan
rout
deliveri
mvavector
vaccin
evalu
recombin
mva
mvaha
hemagglutinin
gene
influenza
viru
rgaviet
insert
delet
iii
site
mva
seri
experi
antibodi
respons
follow
vaccin
via
subcutan
percutan
rout
character
protect
effect
vaccin
via
rout
evalu
mous
intranas
challeng
model
first
experi
group
mice
five
per
group
vaccin
pfu
mvaha
primeboost
schedul
interv
week
vaccin
dose
mvaha
administ
via
subcutan
percutan
rout
control
group
vaccin
pfu
mva
via
subcutan
rout
three
week
vaccin
serum
sampl
obtain
mice
test
igg
mice
challeng
pfu
attenu
influenza
rgaviet
via
intranas
rout
except
mous
mva
control
group
low
level
nonspecif
igg
mice
control
group
igg
includ
one
detect
igg
succumb
influenza
viru
challeng
mice
vaccin
mvaha
irrespect
rout
high
level
igg
titer
fig
protect
influenza
viru
challeng
fig
second
experi
mice
group
mice
five
per
group
vaccin
pfu
mvaha
via
subcutan
percutan
rout
primeboost
schedul
interv
week
vaccin
control
group
vaccin
pfu
mva
subcutan
antisera
obtain
mice
three
week
booster
vaccin
mice
challeng
pfu
influenza
rgaviet
mice
mva
group
detect
igg
contrast
mice
inocul
mvaha
irrespect
dose
high
titer
igg
fig
differ
igg
level
subcutan
percutan
cohort
dose
level
mvaha
statist
signific
although
mean
igg
titer
slightli
higher
subcutan
cohort
follow
intranas
challeng
influenza
rgaviet
mice
mva
group
succumb
infect
mice
vaccin
mvaha
irrespect
dose
surviv
vari
degre
morbid
among
mvaha
vaccin
mice
pfusubcutan
group
record
severest
weight
loss
fig
differ
weight
chang
subcutan
percutan
group
vaccin
pfu
statist
signific
twotail
pvalu
summari
neutral
antibodi
titer
pool
antisera
treatment
group
two
mvaha
experi
describ
present
tabl
mva
control
group
detect
neutral
antibodi
serum
sampl
obtain
time
point
among
group
vaccin
mvaha
neutral
antibodi
detect
postprim
antisera
except
pfu
subcutan
group
titer
obtain
howev
follow
administr
booster
inocul
mvaha
treatment
group
detect
level
neutral
antibodi
increas
increas
vaccin
dose
neutral
antibodi
titer
mice
subcutan
cohort
pfu
respect
similarli
neutral
antibodi
titer
among
percutan
cohort
pfu
respect
interestingli
level
neutral
antibodi
percutan
treatment
group
similar
subcutan
group
mvaha
dosag
spite
slightli
higher
total
igg
level
subcutan
cohort
differ
statist
signific
set
data
suggest
antibodi
respons
total
igg
neutral
antibodi
elicit
mvaha
compar
mice
inocul
via
subcutan
rout
inocul
via
percutan
rout
observ
mice
inocul
pfu
mvaha
primeboost
protect
influenza
viru
challeng
experi
mvaha
describ
mice
vaccin
primeboost
schedul
pfu
mvaha
elicit
antibodi
respons
protect
indistinguish
subcutan
percutan
treatment
cohort
order
scrutin
differ
two
inocul
rout
lower
dose
mvaha
use
experi
one
experi
group
mice
five
per
group
vaccin
mvaha
dose
pfu
dose
administ
via
subcutan
percutan
rout
control
group
inocul
subcutan
pfu
mva
booster
inocul
amount
mvaha
mva
administ
three
week
mice
prime
three
week
booster
dose
mice
challeng
attenu
rgaviet
pfu
per
mous
evalu
daili
two
week
describ
none
anim
vaccin
mva
surviv
mice
vaccin
pfu
mvaha
primeboost
schedul
surviv
pfu
mvaha
group
surviv
subcutan
percutan
group
respect
influenza
viru
pathogenesi
mice
measur
weight
loss
fig
show
doserespons
respect
mvaha
weight
loss
invers
proport
dose
mvaha
major
differ
surviv
rate
mice
subcutan
percutan
group
inocul
dose
mvaha
pfu
mvaha
mean
weight
loss
higher
percutan
group
subcutan
group
differ
statist
signific
twotail
pvalu
final
two
independ
experi
mice
group
five
experi
vaccin
low
dose
mvaha
administ
challeng
three
week
vaccin
group
mice
inocul
dose
pfu
mvaha
subcutan
percutan
control
group
receiv
pfu
mva
subcutan
summari
number
surviv
mice
present
tabl
none
mice
vaccin
mva
surviv
among
mice
mvaha
subcutan
vaccin
cohort
surviv
pfu
pfu
pfu
vaccin
group
respect
similarli
among
mice
percutan
vaccin
cohort
surviv
viral
challeng
mean
weight
loss
among
mice
experi
shown
fig
statist
comparison
number
surviv
mice
show
differ
surviv
mice
vaccin
pfu
mvaha
irrespect
vaccin
rout
mva
control
group
statist
signific
tabl
howev
comparison
observ
differ
surviv
percutan
subcutan
group
pfu
dose
level
indic
differ
statist
signific
set
data
suggest
even
low
vaccin
dose
differ
mous
group
vaccin
via
subcutan
percutan
rout
appar
challeng
model
modifi
vaccinia
viru
ankara
mva
licens
europ
canada
third
gener
smallpox
vaccin
current
clinic
develop
licensur
unit
state
rel
better
safeti
record
mva
compar
first
second
gener
smallpox
vaccin
well
document
addit
larg
capac
accommod
heterolog
gene
express
encod
protein
elicit
humor
cellmedi
immun
respons
also
make
mva
attract
vector
deliveri
sever
candid
vaccin
varieti
infecti
noninfecti
human
veterinari
diseas
evid
deliveri
antigen
skin
asia
date
back
practic
variol
continu
advent
smallpox
vaccin
late
centuri
thu
replicationcompet
smallpox
vaccin
includ
use
success
erad
smallpox
dryvax
lister
livp
templ
heaven
mostli
administ
skin
scarif
current
uslicens
secondgener
smallpox
vaccin
also
administ
skin
scarif
procedur
believ
partli
respons
success
global
erad
smallpox
provok
robust
innat
adapt
immun
respons
due
sever
attenu
mva
epitom
inabl
replic
product
mani
mammalian
cell
mva
mvavector
vaccin
usual
administ
via
rout
percutan
preclin
studi
clinic
investig
mvavector
vaccin
mostli
use
intramuscular
intraderm
rout
lesser
extent
subcutan
inject
rout
local
reactogen
follow
vaccin
mva
mvavector
vaccin
believ
sever
subcutan
intraderm
inocul
via
intramuscular
rout
comparison
safeti
immunogen
mvavector
hiv
vaccin
individu
vaccin
mvahiva
subcutan
intraderm
rout
found
develop
sever
local
reaction
vaccin
via
intramuscular
rout
howev
intramuscular
subcutan
tissu
rel
fewer
antigen
present
cell
skin
tissu
may
adequ
optim
immun
respons
administ
vaccin
infecti
diseas
skin
gener
signific
interest
recent
year
includ
use
deliveri
bcg
tuberculosi
vaccin
boost
develop
microneedl
patch
technolog
deliv
vaccin
intraderm
microneedl
inocul
vaccin
use
preclin
evalu
sever
vaccin
includ
inactiv
polio
vaccin
influenza
vaccin
measl
vaccin
clinic
applic
vaccin
skin
also
document
number
vaccin
includ
influenza
vaccin
rabi
vaccin
recent
studi
suggest
vaccin
deliveri
skin
take
advantag
abund
presenc
skinresid
antigenpres
cell
includ
differ
subset
dendrit
cell
langerhan
cell
well
infiltr
antigen
present
cell
provok
robust
immun
respons
includ
humor
cellmedi
immun
respons
induc
longliv
cell
memori
moreov
data
deliveri
differ
type
vaccin
skin
suggest
live
vaccin
subunit
vaccin
administ
skin
success
immun
outcom
earlier
data
laboratori
well
clinic
trial
suggest
deliveri
modifi
vaccinia
viru
ankara
intraderm
layer
skin
elicit
robust
immun
respons
higher
intramuscular
subcutan
inocul
protect
mice
intranas
challeng
vaccinia
viru
show
sever
attenu
recombin
vaccinia
viru
fail
form
visibl
plaqu
sever
mammalian
cell
line
reminisc
mva
elicit
protect
immun
respons
use
vaccin
mice
scarif
work
describ
expand
investig
deliveri
mva
well
mvavector
antigen
skin
preliminari
experi
observ
igg
titer
higher
mice
receiv
pfu
mva
skin
scarif
mice
receiv
dose
mva
intramuscular
inocul
subsequ
experi
antibodi
respons
protect
mice
vaccin
mva
subcutan
tail
scarif
higher
vaccin
via
intramuscular
rout
melam
et
al
compar
antibodi
respons
elicit
respons
mva
two
recombin
mva
genet
modifi
replic
vero
cell
inocul
mice
intramuscular
inject
tail
scarif
data
indic
tail
scarif
effici
induc
antibodi
respons
although
intramuscular
rout
elicit
higher
geometr
mean
titer
antibodi
confer
higher
surviv
rate
differ
observ
one
report
may
due
differ
experiment
procedur
andor
assay
method
instanc
work
mva
tail
scarif
typic
volum
per
dose
make
easier
handl
use
melam
et
al
subsequ
experi
rout
comparison
limit
subcutan
versu
percutan
rout
sinc
subcutan
rout
commonli
use
vaccin
studi
mva
vector
util
mva
viral
vector
express
heterolog
antigen
expand
also
compar
antibodi
respons
protect
confer
vaccin
two
mva
recombin
one
express
glycoprotein
express
hemagglutinin
influenza
viru
rga
viet
mice
vaccin
tail
scarif
elicit
higher
similar
titer
igg
neutral
antibodi
vaccin
subcutan
inocul
observ
differ
igg
titer
statist
signific
two
rout
pfu
statist
signific
pfu
suggest
percutan
deliveri
may
effect
subcutan
inocul
elicit
neutral
antibodi
lower
vaccin
dose
consist
previou
report
percutan
inocul
also
elicit
cellmedi
immun
respons
evid
secret
restimul
immun
splenocyt
mva
vector
express
influenza
antigen
shown
elicit
protect
immun
respons
anim
model
includ
mice
ferret
macaqu
second
recombin
mva
vaccin
model
mvaha
express
influenza
viru
use
vaccin
mice
subcutan
inject
tail
scarif
antibodi
respons
protect
effect
intranas
challeng
homolog
attenu
influenza
viru
rgaviet
assess
data
indic
compar
level
antibodi
titer
protect
confer
two
immun
rout
interestingli
higher
surviv
rate
among
mice
vaccin
tail
scarif
record
low
vaccin
dose
among
advantag
attribut
skin
deliveri
vaccin
possibl
antigen
dose
spare
data
describ
manuscript
support
earlier
report
lower
dose
mva
mvaha
found
elicit
full
partial
protect
mice
summari
show
mva
recombin
mva
vector
express
influenza
viru
elicit
protect
immun
respons
mous
model
taken
togeth
data
present
work
suggest
mva
mvavector
vaccin
effect
deliv
skin
advantag
antigen
deliveri
skin
requir
volum
least
time
murin
model
time
human
less
volum
use
subcutan
vaccin
comprehens
investig
clinic
benefit
deliv
mva
mvavector
vaccin
skin
necessari
apart
effici
provok
robust
immun
respons
may
also
help
amelior
obliter
commonli
report
volumerel
local
reaction
associ
subcutan
intramuscular
vaccin
deliveri
pain
site
inject
may
accept
peopl
needl
phobia
thu
enhanc
complianc
schedul
immun
program
although
preclin
evalu
vaccin
skin
scarif
describ
studi
involv
use
improvis
needl
scarif
process
prior
applic
vaccin
advanc
develop
microneedl
patch
facilit
painless
applic
vaccin
skin
without
use
hypoderm
inject
needl
bifurc
needl
use
administ
smallpox
vaccin
preclin
studi
microneedl
deliveri
mvavector
vaccin
shown
effect
elicit
robust
immun
respons
malaria
compar
level
attain
intraderm
vaccin
thu
refin
use
microneedl
deliveri
appear
hold
promis
futur
applic
viralvector
vaccin
skin
